Dec. 4, 2024S-4321, a dual-cell bidirectional antibody that agonizes inhibitory receptors at the T cell-APC synapseSeismic Therapeutic Inc. has provided preclinical data for S-4321, a novel dual-cell bidirectional (DcB) PD-1:FcγRIIb antibody being developed for the treatment of autoimmune disease.
Dec. 4, 2024Kronos Bio’s KB-7898 reduces pathological scores in inflammatory disordersKronos Bio Inc. has presented data on KB-7898, an orally available p300 KAT inhibitor.
Dec. 3, 2024PAI-1 inhibitor MDI-2517 shows superior preclinical efficacy in systemic sclerosis modelsResearchers from the University of Michigan Medical School and MDI Therapeutics Inc. recently presented preclinical data for MDI-2517.
